腹腔胃肠道恶性肿瘤术后联合化疗的临床研究及运用.docVIP

腹腔胃肠道恶性肿瘤术后联合化疗的临床研究及运用 郝永钟 朱伟科 解传仁 殷容暖 广东省东莞市常平医院外二区(胃肠外科) 【注】该项目是东莞市科技局医疗卫生类科研立项项目 【摘要】①目的 研究腹腔胃肠道恶性肿瘤术后腹腔、淋巴、静脉联合化疗较传统静脉化疗的优势。②方法 比较6年来腹腔胃肠道恶性肿瘤患者根治术后进行腹腔、淋巴、静脉联合化疗（共136名）的复发率，生存率的差异。③结果 腹腔胃肠道恶性肿瘤术后腹腔、淋巴、静脉联合化疗组患者1、2、3年无瘤生存率分别为83.6%、75.2%和69.3%，疗效明显优于静脉化疗组的1、2、3年无瘤生存率66.7%、54.2%和46.3%（P0.05），两组肿瘤3年腹腔内复发率分别为23.5%和40.7%，差异具有显著性（P0.01）。④结论 作研究术后腹腔化疗较传统静脉化疗的优势。胃肠道After abdominal cavity gastro-intestinal tract malignant tumor technique, unites the chemotherapy the clinical research and the utilization Hao yong-zhong；Zhu wei-ke；Xie chuan-ren；Yin rong-nuan； Guangdong Dongguan Changping hospital surgical department two areas（General surgery） 【ABSTRACT】①After research abdominal cavity gastro-intestinal tract malignant tumor technique, the abdominal cavity, the lymph, the vein union chemotherapy compares the traditional vein chemotherapy the superiority.②After for 6 year abdominal cavity gastro-intestinal tract malignant tumor patient root governing skill carries on the abdominal cavity, the lymph, the vein union chemotherapy (altogether 136) recurrence rate, survival rate difference.③After abdominal cavity gastro-intestinal tract malignant tumor technique, the abdominal cavity, the lymph, the vein union chemotherapy group patient 1, 2, 3 year non-lump survival rate respectively is 83.6%, 75.2% and 69.3%, The curative effect surpasses the vein chemotherapy group 1, 2, 3 year non-lump survival rates 66.7%, 54.2% and 46.3%（P0.05）, in two group of tumor 3 year abdominal cavity the recurrence rate respectively is obviously 23.5% and 40.7%, the difference has the significance（P0.01）.④After gastro-intestinal tract malignant tumor root governing skill the auxiliary chemotherapy method, the abdominal cavity, the lymph, the vein union chemotherapy surpasses the sole vein chemotherapy, regarding reduces in the abdominal cavity in the malignant tumor to recur has the remarkable effect. 【KEY WORLDS】Abdominal cavity; Gastro-intestinal tract; Malignant tumor; Union chemotherapy; 腹